Background: Currently, specific studies identifying how repository corticotropin injection (RCI) is used in rheumatologic conditions are lacking. This is a first step to familiarize the trends of demographics using RCI as well as other medication use. Objective: RCI may produce anti-inflammatory as well as immune-modulatory effects. The purpose of this study is to examine the demographics of those who use RCI and the change in medication use, specifically prednisone, after RCI initiation. Method: This study used the Symphony Health Solutions (SHA) Claims database from 2008 to 2015. International Classification of Disease, Ninth Revision, codes were used to identify rheumatologic conditions including rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, and polymyositis. Information including RCI dose and concomitant medication uses was also obtained. Results: A total of 2749 patients with rheumatologic conditions receiving RCI were investigated for demographic information, and a total of 1048 patients with rheumatologic conditions on RCI were examined for medication use. The use of nonsteroidal anti-inflammatory drugs, disease-modifying anti-rheumatic drugs, and biologics overall decreased significantly in all 3 rheumatologic conditions except biologics in dermatomyositis/polymyositis. In addition, mean prednisone dose before and after RCI use significantly decreased one quarter (12 weeks) after RCI initiation. Conclusion: Claims-based study on RCI use indicates that RCI use might reduce use of prednisone, disease-modifying anti-rheumatic drugs, and other biologics. Further prospective study is needed.
DeckerDAGrantCOhLBeckerPMYoungDJordanS.Immunomodulatory effects of H.P. Acthar Gel on B cell development in the NZB/W F1 mouse model of systemic lupus erythematosus. Lupus. 2014;23:802-812.
2.
GettigJCummingsJPMatuszewskiK. H.P.Acthar gel and cosyntropin review. P T. 2009;34:250-257.
3.
SchiöthHBMucenieceRLarssonMWikbergJE.The melanocortin 1, 3, 4 or 5 receptors do not have a binding epitope for ACTH beyond the sequence of alpha-MSH. J Endocrinol. 1997;155:73-78.
LoramLCCulpMEConnolly-StrongEDSturgill-KoszyckiS.Melanocortin peptides: potential targets in systemic lupus erythematosus. Inflammation. 2015;38:260-271.
6.
ChanLFMetherellLAClarkAJ.Effects of melanocortins on adrenal gland physiology. Eur J Pharmacol. 2011;660:171-180.
7.
MagenisRESmithLNadeauJHJohnsonKRMountjoyKGConeRD.Mapping of the ACTH, MSH, and neural (MC3 and MC4) melanocortin receptors in the mouse and human. Mamm Genome. 1994;5:503-508.
8.
MountjoyKGMortrudMTLowMJSimerlyRBConeRD.Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol. 1994;8:1298-1308.
9.
LasagaMDebeljukLDurandDScimonelliTNCarusoC.Role of alpha-melanocyte stimulating hormone and melanocortin 4 receptor in brain inflammation. Peptides. 2008;29:1825-1835.
10.
MokCCLauCS.Pathogenesis of systemic lupus erythematosus. J Clin Pathol. 2003;56:481-490.
11.
MannaSKAggarwalBB.Alpha-melanocyte-stimulating hormone inhibits the nuclear transcription factor NFkappa B activation induced by various inflammatory agents. J Immunol. 1998;161:2873-2880.
12.
MandrikaIMucenieceRWikbergJE.Effects of melanocortin peptides on lipopolysaccharide/interferon-gamma-induced NF-kappaB DNA binding and nitric oxide production in macrophage-like RAW 264.7 cells: evidence for dual mechanisms of action. Biochem Pharmacol. 2001;61:613-621.
13.
CataniaAGattiSColomboGLiptonJM.Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev. 2004;56:1-29.
14.
CulverDAbrahamSLowerEBaughmanR.Changes in the cytokine profile of sarcoidosis patients treated with Acthar gel [Abstract]. Chest. 2016;150(4 suppl):513A.
15.
FiechtnerJJMontroyT.Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial. Lupus. 2014;23:905-912.
16.
CataniaAGerloniVProcacciaS. The anticytokine neuropeptide α-melanocyte-stimulating hormone in synovial fluid of patients with rheumatic diseases: comparisons with other anticytokine molecules. Neuroimmunomodulation. 1994;1:321-328.
17.
LevineT.Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone (ACTH) gel: a retrospective case series. Drug Des Devel Ther. 2012;6:133-139.
